 |
|
|
|
|
Abstract
In This Issue...
The market for disease-modifying rheumatoid arthritis (RA) therapies is
dominated by sales of three currently marketed tumor necrosis factor-alpha
(TNF-alpha) inhibitors - Enbrel, Remicade, and Humira. Although these agents
are prescribed to a small minority of drug-treated RA patients due to their
high cost and potential to cause serious adverse events, their high price
relative to conventional disease-modifying antirheumatic drugs (DMARDs) is
what drives their commercial success, and in turn, the success of each drug' s
key marketers - Amgen and Wyeth, Centocor and Schering-Plough, and Abbott,
respectively - in the RA market. However, not all RA patients treated with the
currently available TNF-alpha inhibitors respond to these agents, thus there
is commercial opportunity for companies who are able to bring novel TNF-alpha
inhibitors and biologics with alternative mechanisms of action to market.
However, emerging players in the RA market who have recently launched or who
are expected to launch novel RA biologics in the near future - including
Bristol-Myers Squibb, Roche, and UCB - will find it difficult for their new
drugs to challenge the well-established and long-term efficacy and safety
profiles of the three currently marketed TNF-alpha inhibitors.
Questions Answered in This Report
- Competitive dynamics: The competitive landscape for RA biologics
recently became more diversified following the early 2006 launch of two novel
agents, and additional biologics are set to enter the RA market in the coming
years. How have the marketers of the three currently available TNF-alpha
inhibitors positioned their brands for success? Which companies will continue
to succeed in the market, and which will succumb to the heightened level of
competition?
- Market dynamics: Recently launched and emerging RA biologics
include agents with novel mechanisms of action for treating RA, as well as new
anti-TNF-alpha therapies. What level of uptake will these novel biologics
experience? How will they affect sales for the overall disease-modifying RA
therapy market?
- Brand dynamics: The marketers of Enbrel, Remicade, and Humira have
positioned their drugs for continued success in the RA market using a variety
of strategies, including conducting long-term efficacy and safety studies,
expanding their drug' s label to include multiple RA indications, employing
aggressive promotional campaigns, and reformulating their drug to bolster
patient convenience. How important is the use of similar strategies to the
future success of novel RA biologics? Have emerging players in the RA market
learned from these successful strategies, and to what extent have they
employed/will they employ such strategies in bringing their novel agent to
market?
- Key events: The market for RA biologics has recently, and will
continue to become, more diversified and crowded following the launch of new
agents What new drugs are forecasted to enter the RA market between 2005
and 2010 and when will they launch? What products are being developed in the
major RA competitors' pipelines?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Market Analysis: Annualized 5-year sales forecasts presented by
region, drug class, molecule, and brand for 2005 to 2010, including the impact
of key events during the forecast period. Annualized forecast of total
prevalent and diagnosed cases for each of the major markets from 2005 to 2010.
- Company Analysis: Detailed discussion of major competitors
including Wyeth, Amgen, Centocor, Schering-Plough, Abbott, Bristol-Myers
Squibb, and Roche. Includes analysis of each company' s RA product portfolio,
development pipeline, and strategic positioning.
- Brand Analysis: The report features an in-depth discussion of
leading brands in the RA market, including approval history, sales and market
position, SWOT analysis, annualized sales forecast, promotional spending,
on-going life cycle management initiatives, and strategic positioning.
|
|
|
|
|
|
View Cart
